Cytomegalovirus viremia in lung transplantation during and after prophylaxis
- 18 March 2019
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 21 (3) , e13069
Abstract
Background: Lung transplantation has a high risk of cytomegalovirus (CMV) viremia and disease.Methods: Valganciclovir was planned for 6 months in CMV recipient seropositive (R+) lung transplants (LTs) and given long‐term in D+R− LTs. CMV viremia was monitored regularly during and after prophylaxis in all patients.Results: Of 137 LTs, 22 were D+R−, 49 D+R+, 43 D−R+, and 23 D−R−, with median follow up 4.1 years (IQR 2.1‐6.2 years). CMV viremia at any time occurred in 44.5% of LTs. CMV viral load >103 c/mL was uncommon (9/77 episodes). CMV viremia occurred at median 665 days (IQR 271‐1411 days), in 5.1% LTs 12 months. CMV disease occurred in 6 (4.4%) LTs at an overall rate of 1.0 episode per 100 person‐years: two of these cases were organ‐specific disease, four were CMV syndrome. One case of ganciclovir‐resistant CMV was diagnosed. D+R+ and D+R− LTs had higher viremia rates than the D−R+ group. No viremia occurred in D−R− LTs. CMV viremia was not associated with age, gender, type of LT, indication for LT, acute rejection, bronchiolitis obliterans syndrome, or mortality.Conclusions: Prophylaxis for 6 months in D+R+ and D−R+, and past 12 months in D+R− LTs, with long‐term monitoring in all patients using a sensitive assay, and reinstitution of valganciclovir for low‐level viremia was effective at markedly reducing the incidence of CMV disease. CMV D−R− LTs do not need routine CMV monitoring.Keywords
This publication has 20 references indexed in Scilit:
- Cytomegalovirus in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Late-Onset Cytomegalovirus (CMV) in Lung Transplant Recipients: Can CMV Serostatus Guide the Duration of Prophylaxis?American Journal of Transplantation, 2012
- Clinical Utility of Molecular Surveillance for Cytomegalovirus After Antiviral Prophylaxis in High-Risk Solid Organ Transplant RecipientsTransplantation, 2011
- Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant RecipientsTransplantation, 2011
- Drug-resistant cytomegalovirus in transplant recipients: a French cohort studyJournal of Antimicrobial Chemotherapy, 2010
- Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung RejectionThe Journal of Heart and Lung Transplantation, 2007
- Emergence of drug‐resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomesClinical Transplantation, 2007
- Cytomegalovirus and Lung TransplantationAmerican Journal of Transplantation, 2004
- Definitions of Cytomegalovirus Infection and Disease in Transplant RecipientsClinical Infectious Diseases, 2002
- High Incidence of Ganciclovir‐Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive TherapyThe Journal of Infectious Diseases, 2002